190 related articles for article (PubMed ID: 23160756)
1. How do I treat inflammatory breast cancer?
Makower D; Sparano JA
Curr Treat Options Oncol; 2013 Mar; 14(1):66-74. PubMed ID: 23160756
[TBL] [Abstract][Full Text] [Related]
2. Inflammatory breast cancer: a single centre analysis.
Gogia A; Raina V; Deo SV; Shukla NK; Mohanti BK; Sharma DN
Asian Pac J Cancer Prev; 2014; 15(7):3207-10. PubMed ID: 24815472
[TBL] [Abstract][Full Text] [Related]
3. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).
Schneeweiss A; Chia S; Hickish T; Harvey V; Eniu A; Hegg R; Tausch C; Seo JH; Tsai YF; Ratnayake J; McNally V; Ross G; Cortés J
Ann Oncol; 2013 Sep; 24(9):2278-84. PubMed ID: 23704196
[TBL] [Abstract][Full Text] [Related]
4. Modern outcomes of inflammatory breast cancer.
Rehman S; Reddy CA; Tendulkar RD
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):619-24. PubMed ID: 22445003
[TBL] [Abstract][Full Text] [Related]
5. [Systemic treatments of inflammatory breast cancer: an overview].
Monneur A; Bertucci F; Viens P; Gonçalves A
Bull Cancer; 2014 Dec; 101(12):1080-8. PubMed ID: 25475708
[TBL] [Abstract][Full Text] [Related]
6. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant Therapy for HER2-positive Breast Cancer.
Wuerstlein R; Harbeck N
Rev Recent Clin Trials; 2017; 12(2):81-92. PubMed ID: 28164759
[TBL] [Abstract][Full Text] [Related]
8. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.
Untch M; Loibl S; Bischoff J; Eidtmann H; Kaufmann M; Blohmer JU; Hilfrich J; Strumberg D; Fasching PA; Kreienberg R; Tesch H; Hanusch C; Gerber B; Rezai M; Jackisch C; Huober J; Kühn T; Nekljudova V; von Minckwitz G; ;
Lancet Oncol; 2012 Feb; 13(2):135-44. PubMed ID: 22257523
[TBL] [Abstract][Full Text] [Related]
9. HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer.
Kim JW; Kim JH; Im SA; Kim YJ; Han HS; Kim JS; Lee KH; Kim TY; Han SW; Jeon YK; Oh DY; Kim TY; Park IA
Cancer Chemother Pharmacol; 2013 Jul; 72(1):109-15. PubMed ID: 23673443
[TBL] [Abstract][Full Text] [Related]
10. Taxane-based combinations as adjuvant chemotherapy for node-positive ER-positive breast cancer based on 2004-2009 data from the Breast Cancer Registry of the Japanese Breast Cancer Society.
Hojo T; Masuda N; Iwamoto T; Niikura N; Anan K; Aogi K; Ohnishi T; Yamauchi C; Yoshida M; Kinoshita T; Masuoka H; Sagara Y; Sakatani T; Kojima Y; Tsuda H; Kumamaru H; Miyata H; Nakamura S
Breast Cancer; 2020 Jan; 27(1):85-91. PubMed ID: 31327134
[TBL] [Abstract][Full Text] [Related]
11. Updates in anti-HER2 combination therapy.
Burstein H
Clin Adv Hematol Oncol; 2008 Dec; 6(12):873-4. PubMed ID: 19209136
[No Abstract] [Full Text] [Related]
12. Serum epidermal growth factor is associated with prognosis and hormone receptor status in patients with HER2-positive metastatic breast cancer treated with first-line trastuzumab plus taxane chemotherapy.
Kim JW; Kim JH; Im SA; Lee KH; Kim JS; Kim TY; Han SW; Jeon YK; Oh DY; Kim TY; Park IA
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1023-9. PubMed ID: 24036907
[TBL] [Abstract][Full Text] [Related]
13. Inflammatory breast cancer with excellent response to pembrolizumab-chemotherapy combination: A case report.
Kharel Z; Nemer OP; Xi W; Upadhayaya B; Falkson CI; O'Regan RM; Dhakal A
Breast Dis; 2022; 41(1):255-260. PubMed ID: 35599460
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.
Thuss-Patience PC; Shah MA; Ohtsu A; Van Cutsem E; Ajani JA; Castro H; Mansoor W; Chung HC; Bodoky G; Shitara K; Phillips GDL; van der Horst T; Harle-Yge ML; Althaus BL; Kang YK
Lancet Oncol; 2017 May; 18(5):640-653. PubMed ID: 28343975
[TBL] [Abstract][Full Text] [Related]
15. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment.
Dawood S; Merajver SD; Viens P; Vermeulen PB; Swain SM; Buchholz TA; Dirix LY; Levine PH; Lucci A; Krishnamurthy S; Robertson FM; Woodward WA; Yang WT; Ueno NT; Cristofanilli M
Ann Oncol; 2011 Mar; 22(3):515-523. PubMed ID: 20603440
[TBL] [Abstract][Full Text] [Related]
16. The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast Cancer.
Nakhlis F; Regan MM; Warren LE; Bellon JR; Hirshfield-Bartek J; Duggan MM; Dominici LS; Golshan M; Jacene HA; Yeh ED; Mullaney EE; Overmoyer B
Ann Surg Oncol; 2017 Sep; 24(9):2563-2569. PubMed ID: 28560598
[TBL] [Abstract][Full Text] [Related]
17. Development of CNS metastases and survival in patients with inflammatory breast cancer.
Uemura MI; French JT; Hess KR; Liu D; Raghav K; Hortobagyi GN; Arun BK; Valero V; Ueno NT; Alvarez RH; Woodward WA; Debeb BG; Moulder SL; Lim B; Tripathy D; Ibrahim NK
Cancer; 2018 Jun; 124(11):2299-2305. PubMed ID: 29579338
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD).
Yamashita T; Masuda N; Saji S; Araki K; Ito Y; Takano T; Takahashi M; Tsurutani J; Koizumi K; Kitada M; Kojima Y; Sagara Y; Tada H; Iwasa T; Kadoya T; Iwatani T; Hasegawa H; Morita S; Ohno S
Trials; 2020 May; 21(1):391. PubMed ID: 32381018
[TBL] [Abstract][Full Text] [Related]
19. [Chemotherapy for breast cancer refractory to anthracycline, taxane or trastuzumab].
Ito Y; Kobayashi K
Gan To Kagaku Ryoho; 2009 May; 36(5):726-9. PubMed ID: 19461171
[TBL] [Abstract][Full Text] [Related]
20. Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC.
Iwase T; Harano K; Masuda H; Kida K; Hess KR; Wang Y; Dirix L; Van Laere SJ; Lucci A; Krishnamurthy S; Woodward WA; Layman RM; Bertucci F; Ueno NT
BMC Cancer; 2020 May; 20(1):430. PubMed ID: 32423453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
